Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neutrogena Rapid Clear is a topical over-the-counter acne treatment product containing 2% salicylic acid. As a beta-hydroxy acid (BHA), salicylic acid acts as a keratolytic and comedolytic agent by promoting the exfoliation of dead skin cells and penetrating into pores to dissolve sebum and cellular debris. This specific product was utilized as a commercial active comparator in a clinical study sponsored by GlaxoSmithKline (GSK) to evaluate the speed of efficacy of a 3% benzoyl peroxide gel in reducing the swelling and redness of acne vulgaris lesions over a five-day period. While Neutrogena is a brand of Johnson & Johnson, the product's inclusion in GSK's clinical research highlights its role as a standard-of-care reference for rapid-acting acne treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neutrogena Rapid Clear.